Elekta AB Ser. B (EKTA-B.ST) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Leksell Gamma Knife radiosurgery system to treat refractory, drug-resistant mesial temporal lobe epilepsy in adults.
MTLE, a form of epilepsy unresponsive to medication, may now be managed non-invasively by focusing 192 gamma-ray beams on the seizure-origin region, potentially reducing or eliminating seizures without open-skull surgery.
Originally developed in 1968 by Prof. Lars Leksell for functional brain disorders, Gamma Knife has since treated conditions like essential tremor and trigeminal neuralgia in nearly two million patients worldwide.
EKTA_B.ST closed Tuesday's trading at 48.40 SEK, up 0.94 SEK or 1.98 percent on the Nasdaq Stockholm.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.